Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can this new hearing aid beat AirPods? trial launches

NCT ID NCT07572357

Symptom relief Sponsor: Rehear Audiology Company LTD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new hearing aid device (RH210A) in 24 adults with self-perceived mild-to-moderate hearing loss. Participants will compare the investigational device to Apple AirPods Pro with a hearing aid feature. The goal is to see if the new device improves hearing and speech understanding in noise, and to check its safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RH210A hearing aid device
What this could lead to
If successful, this could provide a new, effective over-the-counter option for people with mild-to-moderate hearing loss.
What could go wrong
This is a small early-stage trial with only 24 participants, so results may not apply to everyone. The device is compared to an existing FDA-cleared product, so major breakthroughs are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years * Self-perceived mild-to-moderate hearing difficulties/ hearing loss * Competent smartphone use (able to complete self-fitting via the app) * Able and willing to provide informed consent * HHIA screening consistent with perceived hearing difficulty * Willingness and ability to attend two in-person research appointments * Ability to operate a SmartPhone Exclusion Criteria: * Conductive or mixed hearing loss * Occluding cerumen * Otologic disease/ active ear pathology * Severe or profound hearing loss (PTA \>S0dBHL) (WHO, 2021) * Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421) * Visible deformity of the ear (congenital or traumatic). * Fluid, pus, or blood coming from the ear (e.g., active drainage). * Sudden or rapidly progressive hearing loss within the recent past (often defined as within \~90 days). * Any acute or chronic dizziness or vertigo associated with hearing issues. * Pain or discomfort in or around the ear. * Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal. * Unilateral hearing loss of sudden onset or large asymmetry between ears. * Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies) * Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal. * Unilateral hearing loss of sudden onset or large asymmetry between ears

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hearing impairment, sensorineural are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hearing loss disorder Hearing Loss, Sensorineural sensorineural hearing loss disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hearing impairment, sensorineural Perceived hearing loss

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Acoustic Laboratories

    RECRUITING

    Macquarie Park, New South Wales, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.